Long‐term outcome of prucalopride for chronic constipation: a single‐centre study
Authors:
- 7 May 2015
- journal article
- research article
- Published by Wiley in Colorectal Disease
- Vol. 17 (12) , 1079-1084
Abstract
Aim: Newer 5‐hydroxytryptamine agonists, such as prucalopride, have been demonstrated to be effective in the short term for treatment of chronic constipation. To date, few studies have investigated their medium‐ and long‐term effectiveness.Method: An analysis was carried out of a prospectively maintained database of all patients started on prucalopride for chronic constipation between April 2011 and April 2014. Cleveland Clinic Constipation Score (CCCS) questionnaires were administered before starting treatment with prucalopride and at the first follow‐up visit to assess change in CCCS scores in 50 randomly selected patients.Results: A total of 155 patients (median age: 47 years; seven men) were started on prucalopride in this period. Of these, 16 (10%) had slow‐transit constipation, 31 (20%) had obstructive defaecation syndrome and 30 (19%) had a combination of both. Of these 155 patients, 78% patients were on three or more laxatives at the time of starting prucalopride. Patients were started on 1 mg or 2 mg according to their age. The median follow‐up period was 24 (range: 4–40) months. At the first follow‐up visit, 106 (68%) patients reported good symptomatic improvement, whereas the remainder had no response. Third of initial responders showed decreased efficacy after a median duration of 6 months and needed regular laxatives/irrigation. Of the 50 patients who filled in the CCCS questionnaires (15 patients were nonresponders), 32 (64%) reported improved scores with a median improvement of two points per criterion.Conclusion: This study provides evidence that prolonged use of prucalopride is effective in achieving a sustained benefit in the majority of patients.Keywords
This publication has 14 references indexed in Scilit:
- Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipationAlimentary Pharmacology & Therapeutics, 2013
- The use of prucalopride in real life for the treatment of constipation subtypes: ups and downsTechniques in Coloproctology, 2013
- The association between prucalopride efficacy and constipation typeTechniques in Coloproctology, 2013
- Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation ‐ a comparison in a controlled environmentAlimentary Pharmacology & Therapeutics, 2013
- Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo‐obstruction – a double‐blind, placebo‐controlled, cross‐over, multiple n = 1 studyAlimentary Pharmacology & Therapeutics, 2011
- Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysisAmerican Journal of Gastroenterology, 2011
- Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate reliefHealth Technology Assessment, 2011
- Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2008
- A Placebo-Controlled Trial of Prucalopride for Severe Chronic ConstipationNew England Journal of Medicine, 2008
- A constipation scoring system to simplify evaluation and management of constipated patientsDiseases of the Colon & Rectum, 1996